SB202190 (FHPI)

Catalog No.S1077

Molecular Weight(MW): 331.34

SB202190 (FHPI) is a potent p38 MAPK inhibitor targeting p38α/β with IC50 of 50 nM/100 nM in cell-free assays, sometimes used instead of SB 203580 to investigate potential roles for SAPK2a/p38 in vivo.

Cited by 17 Publications

Nat Commun, 2014, 5:3479

PubMed: 24632940 ( click the link to review the publication )

Clin Cancer Res, 2016, 10.1158/1078-0432.CCR-15-2242

PubMed: 27297582 ( click the link to review the publication )

Biomaterials, 2017, 128:44-55

PubMed: 28288348 ( click the link to review the publication )

Mol Syst Biol, 2015, 11(3):797

PubMed: 25814555 ( click the link to review the publication )

Free Radic Biol Med, 2017, 104:280-297

PubMed: 28131902 ( click the link to review the publication )

J Biol Chem, 2010, 285(43):32824-33

PubMed: 20729213 ( click the link to review the publication )

Toxicol Appl Pharmacol, 2016, 303:79-89

PubMed: 27174766 ( click the link to review the publication )

Chem Res Toxicol, 2014, 27(9):1575-85

PubMed: 25148906 ( click the link to review the publication )

BMC Cancer, 2014, 14:325

PubMed: ( click the link to review the publication )

J Cancer, 2016, 7(8):900-9

PubMed: 27313779 ( click the link to review the publication )

Life Sci, 2014, 108(2):63-70

PubMed: 24857982 ( click the link to review the publication )

Int Immunopharmacol, 2014, 24(1): 50-58

PubMed: 25479727 ( click the link to review the publication )
J Cell Biochem, 2014, 115(5):874-88

PubMed: 24375433 ( click the link to review the publication )

Cell Transplant, 2014, 23(4-5):641-56

PubMed: 24816456 ( click the link to review the publication )

PLoS One, 2013, 8(9):e73548

PubMed: 24019927 ( click the link to review the publication )

Mol Biosyst, 2014, 10(3):605-12

PubMed: 24413303 ( click the link to review the publication )

Anticancer Agents Med Chem, 2014, 14(8):1154-60

PubMed: 24934165 ( click the link to review the publication )

3 Customer Reviews

C, Jurkat cells with SB202190 at 1, 5, and 10 μM were tested, and a decreased SRP72 expression was found when using at 10 μM (lanes 8 and 9). D, results were analyzed and RUA illustrated, finding significant results at 10 μM at 240 versus 0 and 120 versus 0 min (p<0.05).

J Biol Chem 2010 285, 32824–32833. SB202190 (FHPI) purchased from Selleck.

C, effect of SB202190 (1, 5, and 10 μM) on SRP72 phosphorylation was tested. A decreased intensity of SRP72 expression when used at 1 μM (240 min) and 5 and 10 μM (120 and 240 min) was found. D, RUA illustrated obtaining significant results at concentration 5 and 10 μM at 120 versus 0 and 240 versus 0 min. * indicates p<0.05.

J Biol Chem 2010 285, 32824–32833. SB202190 (FHPI) purchased from Selleck.
We used real time RT-PCR to investigate the effects of SB202190 on SRP72 mRNA expression. All the samples were treated under the same experimental conditions used in protein tests done by WB, and phosphorylation was measured indirectly by IP-WB. The results did not show significant changes on the mRNA expression of SRP72 after the treatment with these inhibitors.

J Biol Chem 2010 285, 32824–32833. SB202190 (FHPI) purchased from Selleck.

Purity & Quality Control

Choose Selective p38 MAPK Inhibitors

Biological Activity

Description

Targets

p38α ^[1] (Cell-free assay)	p38β ^[1] (Cell-free assay)
50 nM	100 nM

In vitro

SB 202190 significantly inhibits both basal and anti-Fas antibody-induced MAPKAPK 2 activity in a dose-dependent manner. SB202190 by itself is sufficient to induce cell death in Jurkat and HeLa cells through activation of CPP32-like caspases, which can be blocked by expression of bcl-2. SB202190-induced apoptosis is attenuated by p38β but augmented by p38α. ^[2] SB 202190 strongly inhibits UVB induced COX-2 protein expression in HaCaT cells, and markedly inhibits UVB induced cox-2 mRNA. ^[3] SB 202190 treatment inhibits the expression of albumin-induced proinflammatory (monocyte chemoattractant protein-1) and transforming growth factor (TGF)-beta1-induced profibrotic (procollagen-Ialpha1) genes over 50% in renal tubular cells (normal rat kidney-52E). ^[4] SB 202190 treatment induces phosphorylation of JNK in a dose- and time- dependent manner in A549 cells, induces phosphorylation of ATF-2 transcription factor, and increases AP-1 DNA binding. ^[6] SB 202190 treatment enhances the growth of THP-1 and MV4-11 cells. SB 202190 increases the phosphorylation of c-Raf and ERK, suggesting that Ras-Raf-MEK-mitogen-activated protein kinase (MAPK) pathway activation is involved in the leukemia cell growth induced by SB 202190. ^[7]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
HCT-116	NV3CU41xTnWwY4Tpc44hSXO\|YYm=	NF7GOXkzPSEQvF2=	NULGSHVTOzBibXnu	NUfEV\|NSTE2VT9Mg	Ml7ZZZR1\W63YYTld{B1cGVibWLORUBidmRicILveIVqdiCneIDy[ZN{cW:wIH;mJIhDTC1{IHnuJJJme3CxboPpeoUhfG9iRFG=	MYKyOlIzOzJ3MR?=
MDA-MB-231	MYDGeY5kfGmxbjDBd5NigQ>?	NFvTR2MzKM7:TR?=	MlnENlQhcA>?		MlSzcIV{e2WwZYOgR2NNOiCrbnT1Z5Rqd25iYomgWG5H\|rF?	M2HMXlI3OTByOES4
rBMSCs	NXfBbHU5TnWwY4Tpc44hSXO\|YYm=	MoLCNVAh\|ryP	NF\pXZozNjViaB?=		NV;obVBt\GWycnXzd4V{KHSqZTDwbI9{eGixconsZZRqd25ib3[gSXJMKGGwZDDwN\|g>	M13yNVI3ODV\|Mk[2
MG63	NYL5TWxzTnWwY4Tpc44hSXO\|YYm=	NHLoSngyOC9{MD:zNEDPxE1?	M2nnTVI1KGh?		MV\zbYdvcW[rY3HueIx6KGSnY4LlZZNmeyC2aHWgcIV3\Wxib3[gdIhwe3Cqb4L5cIF1\WRicEO4JIlv\HWlZXSgZpkhS2SFbEKgbY4h[SClb37j[Y51emG2aX;uJE1l\XCnbnTlcpQhdWGwbnXy	MkjnNlU6QTh\|MUK=
MG63	NIDhSXdCeG:ydH;zbZMhSXO\|YYm=	M3nEVFExNzJyL{OwJO69VQ>?	M4jwR\|I1KGh?		M3LaWpNq\26rZnnjZY51dHliZHXjdoVie2WmIITo[UBieG:ydH;zbZMhemG2ZTDv[kBOTzZ\|IHnu[JVk\WRiYomgR4REdDJ?	MkDQNlU6QTh\|MUK=
HTSMCs	MoXuSpVv[3Srb36gRZN{[Xl?	NUfIZWtmOC5zL{GvNVAh\|ryP	Ml[0NUBp		NXnlPJZIcW6qaXLpeIVlKEORUl2tNk1qdmS3Y3XkJGhQNTFicILveIVqdiCuZY\lcJMh[W6mIH3SUmEh\XiycnXzd4lwdg>?	MnjKNlU6OjF2NkS=
MIA PaCa-2	NE\kVXRHfW6ldHnvckBCe3OjeR?=	MnLINlDDqM7:TR?=	M17tN\|I1KGh?		MWLy[YR2[2WmIHzhZ5RifGViYXPjeY12dGG2aX;uJIlvKGOxbXLpcoF1cW:wIIfpeIgh[m:2aDCyMWRIKGGwZDDEMYFtdG:\|ZdMg	MormNlU5QDh2OEm=
MIA PaCa-2	M3TYVmZ2dmO2aX;uJGF{e2G7	M2eweFIxyqEQvF2=	NYPZeYZHOjRiaB?=		MVXy[ZN2dHS\|IHnuJIEhdW:mZYP0JIlvcGmkaYTpc44hd2ZiSFnGMVHPuSCycn;0[YlvKGGlY4XteYxifGmxbh?=	NWnPWnNbOjV6OEi0PFk>
BxPC-3	NH;CbmJHfW6ldHnvckBCe3OjeR?=	MX[yNOKh\|ryP	MmTTNlQhcA>?		MUXy[ZN2dHS\|IHnuJIEhdW:mZYP0JIlvcGmkaYTpc44hd2ZiSFnGMVHPuSCycn;0[YlvKGGlY4XteYxifGmxbh?=	NHLIVFgzPTh6OES4PS=>
AsPC-1	MlPnSpVv[3Srb36gRZN{[Xl?	MVGyNOKh\|ryP	MlTMNlQhcA>?		M2LLNpJme3WudIOgbY4h[SCvb3Tld5QhcW6qaXLpeIlwdiCxZjDITWYuOc7zIIDyc5RmcW5iYXPjeY12dGG2aX;u	MmXNNlU5QDh2OEm=
MIA PaCa-2	M3HJ[2Z2dmO2aX;uJGF{e2G7	MXOyNOKh\|ryP	Mki4NlQhcA>?		NXv2NHBs\W6qYX7j[ZMh[2ynYY\h[4Uhd2ZiUFHSVEB4cGWwIHPvcYJqdmWmIIfpeIgh\2y3Y3;z[UBidmGub3fz	NYjmUI9NOjV6OEi0PFk>
MIA PaCa-2	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYryW3VjOjEEoN88US=>	M2r1cFIhcA>?		NWrye5NJe2Wwc3n0bZpmeyClZXzsJIxqdmW\|IITvJJRz\WG2bXXueEB4cXSqIEKtSGch[W6mIFStZYxtd3On	MnXCNlU5QDh2OEm=
BxPC-3	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWLs[WFFOjEEoN88US=>	M2nsZ\|IhcA>?		M3SwcJNmdnOrdHn6[ZMh[2WubDDsbY5meyC2bzD0doVifG2nboSge4l1cCB{LVTHJIFv\CCGLXHscI9{\Q>?	MVSyOVg5QDR6OR?=
AsPC-1	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnP5NlDDqM7:TR?=	M331U\|IhcA>?		MULz[Y5{cXSrenXzJINmdGxibHnu[ZMhfG9idILlZZRu\W62IIfpeIghOi2GRzDhcoQhTC2jbHzvd4U>	NVfCOnZkOjV6OEi0PFk>
HEY	M{C1dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXeyNOKh\|ryP	M1e5VlIhcA>?		M1fEb5NmdnOrdHn6[ZMh[2WubDDsbY5meyC2bzD0doVifG2nboSge4l1cCB{LVTHJIFv\CCGLXHscI9{\Q>?	MljBNlU5QDh2OEm=
OVCAR-3	MoGxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIHYW4wzOMLizszN	M1nLOlIhcA>?		NVTTc211e2Wwc3n0bZpmeyClZXzsJIxqdmW\|IITvJJRz\WG2bXXueEB4cXSqIEKtSGch[W6mIFStZYxtd3On	NELj[4IzPTh6OES4PS=>
SK-OV-3	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX:5TXM5OjEEoN88US=>	Mn7FNkBp		M{LLTpNmdnOrdHn6[ZMh[2WubDDsbY5meyC2bzD0doVifG2nboSge4l1cCB{LVTHJIFv\CCGLXHscI9{\Q>?	NHPoSG4zPTh6OES4PS=>
MH7A	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MlPQNlQhcA>?		M2THeJJmcW6ob4Lj[ZMhfGinIHnubIljcXSxcomg[YZn\WO2czDv[kBZSU5?	NXPSfGh1OjV6NkK5OlY>
MH7A	NXL4U3B5SXCxcITvd4l{KEG\|c3H5	MUeyOUDPxE1?	MknZNlQhcA>?		M1P5VJJmfmW{c3XzJINmdGxiY4njcIUh[XK{ZYP0JIlv\HWlZXSgZpkhYEGQIHHu[EBk[XW\|ZXSgZZBweHSxc3nzJI9nKGOnbHzzJJZq[SCjY4TpeoF1cW:wIH;mJGpPUw>?	Mn\oNlU5PjJ7Nk[=
SCC25	Mm\sSpVv[3Srb36gRZN{[Xl?	Ml\mNlAh\|ryP	MYSyOEBp		MUnpcoNz\WG\|ZYOgZZV1d3CqYXf5JIxmfmWu	NGrFNnczPTh\|NESwNC=>
HaCaT	M1vOUGZ2dmO2aX;uJGF{e2G7	MnrTOUDDvU1?	MX6yOEBp		NUPF[pBzcW6qaXLpeJMhUU[QLd8zMYlv\HWlZXSgR2NNOjJicILv[JVkfGmxbjDs[ZZmdHN?	NVrU[3BPOjV6M{SzOVM>
HaCaT	NFrMU2dHfW6ldHnvckBCe3OjeR?=	MVy1JOK2VQ>?	NUDadXpvOjRiaB?=		MnPFbY5pcWKrdIOgTWZPNc7zLXnu[JVk\WRiQ1PMNlIheHKxZIXjeIlwdiCuZY\lcJM>	NV[3b286OjV6M{SzOVM>
HPAEpiCs	MXzGeY5kfGmxbjDBd5NigQ>?	M{X5U\|EwOy9zMDFOwG0>	MXmxJIg>		MXvy[YR2[2W\|IGOxVE1qdmS3Y3XkJGlESU1vMTDwdo91\WmwIHHu[EBuWk6DIHX4dJJme3Orb36gZY5lKHC{b33veIVzKGGldHn2bZR6	Ml3JNlU4OzR7MEC=
HPAEpiCs	MVvGeY5kfGmxbjDBd5NigQ>?	NIGzeFcyNzNxMUCg{txO	M1\kcVEhcA>?		NUHoe4kxcW6qaXLpeJMhWzGSLYP0bY12dGG2ZXSgRYt1KHCqb4PwbI9zgWyjdHnvckAhyqB?	MXeyOVc{PDlyMB?=
HPAEpiCs	M4fyZWZ2dmO2aX;uJGF{e2G7	NYG3W\|F7OS9\|L{GwJO69VQ>?	NHixbGcyKGh?		M33RUIlvcGmkaYTzJHMyWCC2aX3lMYRmeGWwZHXueIx6KHO2aX31cIF1\WRiYz3KeY4heGixc4Doc5J6dGG2aX;u	MnnZNlU4OzR7MEC=
K562	NFTMSpFHfW6ldHnvckBCe3OjeR?=	NXPnXIZ{OTEEoN88US=>	Mn;uNeKhcA>?	NVqwdnpQTE2VTx?=	NETOWFVqdmirYnn0d{ByfWmwYXPybY5mNWmwZIXj[YQheDN6IF3BVGsheGixc4Doc5J6dGG2aX;u	MonSNlU3QDRyNEO=
PANC-1	NXzteotFTnWwY4Tpc44hSXO\|YYm=	NYq4UJhWOTBizszN	M3;oRVEhcA>?		M{fDdoVvcGGwY3XzJJRp\SCjdYTvdIhi\2mlIHXm[oVkfMLi	NELIPZEzPTZ\|MkKyNi=>
BxPC-3	NWq0V3J[TnWwY4Tpc44hSXO\|YYm=	MVuxNEDPxE1?	Mlu3NUBp		MXzlcohidmOnczD0bIUh[XW2b4DoZYdq[yCnZn\lZ5TDqA>?	NEDlclYzPTZ\|MkKyNi=>
K562	NHLGW4pHfW6ldHnvckBCe3OjeR?=	NELQbIUxNjJ3LUGg{txO	MXuyOEBp		NVfqb5Fre3WycILld5NmeyC{ZYP2[ZJifHKxbD3pcoR2[2WmIFiyRXgheGixc4Doc5J6dGG2aX;u	NImyVnkzPTZzOUO5Ni=>
THP-1	MVrGeY5kfGmxbjDBd5NigQ>?	NYrnNnFJPSEEtV2=	Ml\4NkBp		M1G3WpNq\26rZnnjZY51dHliYYT0[Y52[XSnczDz[YNz\XSrb36gc4YhUUxvMd8xJIlv\HWlZXSgZpkhOjeRSFPoc4wheGy3czDGV2wuOcLi	NUXq[2MyOjV3OUi2OlE>
WB	NGLiVoZHfW6ldHnvckBCe3OjeR?=	M2jXZVIx6oDLzszNxsA>	M3y3fFMx6oDLbXnu		NHLxWnNl\WO{ZXHz[ZMhfGinIFzQV{0hd3JiTGTBMYlv\HWlZXSgTWwuPiCjbnSgWG5HNc7zwrDwdo9lfWO2aX;u	M1zrR\|I2PTNyNkiy
RAW 264.7	NUDt[lQ{TnWwY4Tpc44hSXO\|YYm=	NYP6PXNMOTEEoN88US=>	NHLxWXM{OOLCiX3pci=>		NUP0dINucW6mdXPld{BkcGG{YXP0[ZJqe3SrYzD2ZYN2d2yjdHnvckBw\iCRQ4RCpC=>	NFLjeG0zPTR4MUO5PS=>
RAW 264.7	NU\3fVNVTnWwY4Tpc44hSXO\|YYm=	MmfXNVDDqM7:TR?=	M1LZZVMx6oDLbXnu		MU\heJRmdnWjdHXzJJRp\SCnZn\lZ5R{KG:oIF;QS{BwdiCxc4Tlc4Nt[XO2IILleJJi[3Srb36=	MXqyOVQ3OTN7OR?=
HaCaT	NVPNWo1ZTnWwY4Tpc44hSXO\|YYm=	MUm0NOKh\|ryP	MXyzMVI1KGh?	NViwcYJ2TE2VTx?=	MXvy[YR2[2W\|IITo[UBi[2O3bYXsZZRqd25ib3[gXm8uOQ>?	NHHrbJYzPTR\|NUS4OS=>
H9c2	NFvoVZRHfW6ldHnvckBCe3OjeR?=	MmO5OVDDqM7:TdMg	M{K3RlEzKGh?		MWLy[YR2[2W\|IFzETEBz\WynYYPlJIFv\CCPTWCgcI9{ew>?	NXH2S5dGOjV{NEW4NVg>
HSCs	NUDVSmQ2SXCxcITvd4l{KEG\|c3H5	M2PV[\|I2KM7:TR?=	M3\nZVI1yqCq		NGq3e5l{cWewaX\pZ4FvfGy7IHH0eIVvfWG2ZYOgWGcucW6mdXPl[EBi[3SrdnH0[YQhUFOFczDhdI9xfG:\|aYO=	MlnoNlQ6PjF7NUC=
THP-1	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NF[4cJk4OiCq	NVG5VJFRTE2VTx?=	MYLJR\|UxRTRwN988US=>	NWDmTVk{OjR6MUWwPFc>
MDDCs	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NWjDRW9vPzJiaB?=	MWrEUXNQ	MmS2TWM2ODJwN988US=>	NUft[HRuOjR6MUWwPFc>
MDDCs	MmHPSpVv[3Srb36gRZN{[Xl?	MnvTNE0yPSEQvF2=	M2T1e\|Q5KGh?	NHPqcJhFVVOR	MXLzeZBxemW\|c3XzJGlHVi4QsTDhcoQhUVBvMUCgdJJw\HWldHnvcuKh	NWjQdmZvOjR6MUWwPFc>
MDDCs	NGfTRXhHfW6ldHnvckBCe3OjeR?=	MljsNE0yPSEQvF2=	MVG0PEBp	NXPH[mpwTE2VTx?=	NH63VINqdmirYnn0d{BOUVBvMXGsJG1KWC1zYjDhcoQhWkGQVFXTJJBzd2S3Y4Tpc44>	M3;abVI1QDF3MEi3
MDDCs	NWjkZmJqTnWwY4Tpc44hSXO\|YYm=	MmTsNVAh\|ryP	NFnNbVg{NjViaB?=	MYjEUXNQ	M4PB[oJtd2OtczDFRm9XKEeSLDDieZQhdm:2IG\TWkBIKG2nZHnheIVlKGWwdIL5JIlvfG9iaIXtZY4hVUSGQ4O=	MWGyOFgyPTB6Nx?=
macrophages	MlTxSpVv[3Srb36gRZN{[Xl?	MVix5qCK\|ryP	NXjjSXhZPC534pEJbC=>		NX;DVGdj[2:vcHzleIVtgSCrbnjpZol1eyCPVD3JTWkucW6mdXPl[EBi[3SrdnH0bY9vKG:oIF7GMe67Sg>?	NYPndJJGOjR6MEi2N\|M>
PDL	MXXGeY5kfGmxbjDBd5NigQ>?	NIjKW5YzOMLizszNxsA>	M1XSbFMxKG2rbh?=	MmHTSG1UVw>?	MnzYd4lodmmoaXPhcpRtgSCrbnjpZol1eyC2aHWgeIVve2muZTDmc5Jk\S2vZXTpZZRm\CCETWCtNkBmgHC{ZYPzbY9v	NYDGTXJKOjR3NkGwPFE>
AGS	MXvGeY5kfGmxbjDBd5NigQ>?	NI\KV2Y2KM7:TR?=	NGLOZmQ{OCCvaX6=		M3nRfJN2eHC{ZYPz[ZPDqDFvaX7keYNm\CClYYPwZZNmNThiYX7kJINie3Cjc3WtN{Bi[3SrdnH0bY9v	MVGyOFU1Pzh5OB?=
H520	MVTGeY5kfGmxbjDBd5NigQ>?	M{TkVFExyqEEtV2=	M2XENVEhcA>?	NXvWWppUTE2VTx?=	NWXHUWl5\GWlcnXhd4V{KHSqZTDw[Y1mfHKneHXkMYlv\HWlZXSgUXNJOiCvUl7BJIFv\CCycn;0[YlvKGyndnXsdy=>	NWno[pprOjR3M{C0O\|U>
H1703	MUXGeY5kfGmxbjDBd5NigQ>?	NWjHUpZnOTEEoNM1US=>	MkDrNUBp	NVzDUI5GTE2VTx?=	NFHj[oVl\WO{ZXHz[ZMhfGinIIDlcYV1emW6ZXStbY5lfWOnZDDNV2gzKG2UTlGgZY5lKHC{b4TlbY4hdGW4ZXzz	NYfiPIsyOjR3M{C0O\|U>
H520	M1vvemZ2dmO2aX;uJGF{e2G7	M1jGSVExyqEEtV2=	MUixNkBp	NYXEW2lXTE2VTx?=	NGXxVodqdmirYnn0d{Bx\W2ndILlfIVlNWWuaXPpeIVlKE2VSEKgdJJwfGWrbjDzeIFjcWyrdIm=	MnnNNlQ2OzB2N{W=
H1703	NHTQPGNHfW6ldHnvckBCe3OjeR?=	Mkm2NVDDqML3TR?=	NV7XOIl7OTJiaB?=	NYDnXnFZTE2VTx?=	MnLPbY5pcWKrdIOgdIVu\XS{ZYjl[E1mdGmlaYTl[EBOW0h{IIDyc5RmcW5ic4ThZoltcXS7	M3zIb\|I1PTNyNEe1
H520	M3nZOWZ2dmO2aX;uJGF{e2G7	NUHkWIVPOTEEoNM1US=>	NHz3UIY3KGh?	M176XWROW09?	Mmjvd4lodmmoaXPhcpRtgSCrbnPy[YF{\XNidHjlJIxmfmWuczDv[kB2[mmzdXn0bY4u[2:waoXnZZRm\CCPU1iyJIlvKHCnbXX0doV5\WRvdILlZZRm\MLiY3XscEBtcW6n	NEDtOWMzPDV\|MES3OS=>
H1703	NYW3TJFrTnWwY4Tpc44hSXO\|YYm=	MnT6NVDDqML3TR?=	NIHCcYw3KGh?	NXn2WYZyTE2VTx?=	MnLBd4lodmmoaXPhcpRtgSCrbnPy[YF{\XNidHjlJIxmfmWuczDv[kB2[mmzdXn0bY4u[2:waoXnZZRm\CCPU1iyJIlvKHCnbXX0doV5\WRvdILlZZRm\MLiY3XscEBtcW6n	MUSyOFU{ODR5NR?=
MC3T3-E1	M1vibmZ2dmO2aX;uJGF{e2G7	MVywMlMwOy9\|MDFOwG0>	NE\LbGYyKGh?		M2mydoF1fGWwdXH0[ZMhXE6ILd8xMYlv\HWlZXSgUW1RNTliZYjwdoV{e2mxbjDpckBiKGOxbnPlcpRz[XSrb36t[IVx\W6mZX70JI1idm6nctMg	NWfIU4ZVOjR3MEK2PVY>
MC3T3-E1	M{TLN2Z2dmO2aX;uJGF{e2G7	MnvkN\|Ah\|ryP	MWSxJIg>		M4T0cIF1fGWwdXH0[ZMhXE6ILd8xMZN1cW23bHH0[YQheDN6IF3BVGsheGixc4Doc5J6dGG2aX;u	MlnkNlQ2ODJ4OU[=
HUVECs	MnzoSpVv[3Srb36gRZN{[Xl?	NUnIdWtvOTEEoNM1US=>	M{G2dlEhcA>?		MXzpcohq[mm2czDUUmYu\|rFvaX7keYNm\CCFWFPMNUBxem:mdXP0bY9v	M4fObFI1PDh5OU[0
AGS	NF\BSmZHfW6ldHnvckBCe3OjeR?=	M{f1TlExyqEEtV2=	MlvsN\|DDqG2rbh?=		NVv4NnhPcW6qaXLpeJMhUUxvMd8yMYlv\HWlZXSgZYN1cX[jdHnvckBw\iCyM{i=	M371UVI1PDd7Nkix
MKN-45	M3;T[mZ2dmO2aX;uJGF{e2G7	MXWxNOKhyrWP	Mlf3N\|DDqG2rbh?=		NHnNWWtqdmirYnn0d{BKVC1zzsKtbY5lfWOnZDDhZ5RqfmG2aX;uJI9nKHB\|OB?=	MV2yOFQ4QTZ6MR?=
AGS	M4PwOGZ2dmO2aX;uJGF{e2G7	Mn6wNVDDqML3TR?=	NUHpUHNNOzEEoH3pci=>		NUHTOpFr[XS2ZX71ZZRmeyCLTD2x{tIucW6mdXPl[EBISSClZXzsJI1q\3KjdHnvckBidmRiaX72ZZNqd25?	MXuyOFQ4QTZ6MR?=
MKN-45	NV;xV5VKTnWwY4Tpc44hSXO\|YYm=	NEDQb3kyOMLiwsXN	MnXvN\|DDqG2rbh?=		NVnw[ppv[XS2ZX71ZZRmeyCLTD2x{tIucW6mdXPl[EBISSClZXzsJI1q\3KjdHnvckBidmRiaX72ZZNqd25?	NUDY[2tbOjR2N{m2PFE>
AGS	NEfxPWZHfW6ldHnvckBCe3OjeR?=	MUmxNOKhyrWP	NGPtV3Y{OMLibXnu		M3jwdpNq\26rZnnjZY51dHliZHXjdoVie2W\|IFnsMVHPui2rbnT1Z4VlKE2PUEKgZY5lKE2PUEmgcXJPSSCneIDy[ZN{cW:w	NIPXfmYzPDR5OU[4NS=>
MKN-45	M{fPZ2Z2dmO2aX;uJGF{e2G7	MlqxNVDDqML3TR?=	NEno[2o{OMLibXnu		MmHKd4lodmmoaXPhcpRtgSCmZXPy[YF{\XNiSXytNe6zNWmwZIXj[YQhVU2SMjDhcoQhVU2SOTDtVm5CKGW6cILld5Nqd25?	NYLjTGZVOjR2N{m2PFE>
DCs	NWTrWI86TnWwY4Tpc44hSXO\|YYm=	NETQXWYzOMLizszN	MmLHNeKhcA>?		M1;LbIRm[3KnYYPld{BKVC1zMjDwdo9lfWO2aX;u	MnzTNlQ1OzR4M{[=
HUVEC	NGS3dppHfW6ldHnvckBCe3OjeR?=	MUmyNEDPxG4EoB?=	NY\2TVFMPSCq	NYrMZo1XTE2VTx?=	NWDjRm5PemWmdXPld{BkgXSxa3nu[UBmgHC{ZYPzbY9vKGyndnXsd{BqdiCjIHPvcoNmdnS{YYTpc44u\GWyZX7k[Y51KG2jbn7ldi=>	M3zEdVI1OTh7ME[y
A 549	NGrIXXlHfW6ldHnvckBCe3OjeR?=	M2\J[VUxKM7:TR?=	NYH2cWFwOSCq		MXHk[YNz\WG\|ZYOgeIhmKGyndnXsJI9nKEmOLUlCpC=>	NIjzZW8zPDF5OU[4PC=>
H520	NX:1elVETnWwY4Tpc44hSXO\|YYm=	M33seFUwOTBizszN	NUewfnVtOSCq	M2O2fWROW09?	NVi5PIV7\GWlcnXhd4V{KE2VSEKgdJJwfGWrbjDhd{B4\WyuIHHzJI1TVkFibHX2[Yx{KGmwIHfl[ol1cW6rYj3lfJBwe2WmIHPlcIw>	NFfOW2QzPDF\|OEmwNy=>
H1703	NVnST4tETnWwY4Tpc44hSXO\|YYm=	MUm1M\|ExKM7:TR?=	M3jvNFEhcA>?	MoPwSG1UVw>?	M1PDSYRm[3KnYYPld{BOW0h{IIDyc5RmcW5iYYOge4VtdCCjczDtVm5CKGyndnXsd{BqdiCpZX\peIlvcWJvZYjwc5Nm\CClZXzs	Mon3NlQyOzh7MEO=
H520	MkTQSpVv[3Srb36gRZN{[Xl?	NWHr[pBoOTEEoNM1US=>	MVmxNkBp	MljtSG1UVw>?	NFjtXIdl\WO{ZXHz[ZMhVVOKMjDtVm5CKGGwZDDwdo91\WmwIIP0ZYJqdGm2eTDpckBo\W[rdHnubYIufHKnYYTl[EBPW0OOQzDj[Yxtew>?	NGnWRWYzPDF\|OEmwNy=>
H1703	MmfsSpVv[3Srb36gRZN{[Xl?	NFHZSWYyOMLiwsXN	NFPFWmgyOiCq	NILqU\|RFVVOR	M4\aZoRm[3KnYYPld{BOW0h{IH3SUmEh[W6mIIDyc5RmcW5ic4ThZoltcXS7IHnuJIdm\mm2aX7pZk11emWjdHXkJG5US0yFIHPlcIx{	NXPWdFZqOjRzM{i5NFM>
MCF-7	M{DHeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1vme\|ExyqEQvF2=	MUKyOOKhcA>?		M2myXYlvcGmkaYTzJJRp\SCFUkGwPE1qdmS3Y3XkJINmdGxiZHXheIg>	Mmf4NlQyOjh6NUO=
HPAEpiCs	MnX1SpVv[3Srb36gRZN{[Xl?	NXi4WoNXOC5zL{GvNVAh\|ryP	NG\FZpQyKGh?		Ml3SbY5pcWKrdIOgWG5HNc7zLXnu[JVk\WRiY2DMRVLDqHC{b4TlbY4h[W6mIH3SUmEh\XiycnXzd4lwdg>?	M4HLZlI1ODZ7MUW4
podocytes	MoniSpVv[3Srb36gRZN{[Xl?	NEnwW3UyOMLizszN	MVmxJIg>		NVrhbm85cW6qaXLpeJMhXEeIzsKxMYlv\HWlZXSgZYN1cX[jdHnvckBw\iCyM{jNRXBMKGGwZDDFdosyNzMEoB?=	NWXZNWhUOjRyM{[yNVI>
MCF-7	NUPsXG03TnWwY4Tpc44hSXO\|YYm=	NUXhSohwOTEEoN88US=>	M{jIPVEhcA>?	M1zHZ2ROW09?	NFK2dolz\WS3Y3XzJJRp\SCZQT3pcoR2[2WmIIDoc5NxcG:{eXzheIVlKHB\|ODDNRXBM	NUT4cYpFOjRyMUmwPVA>
MCF-7	NGnNWldHfW6ldHnvckBCe3OjeR?=	M2Lte\|ExyqEQvF2=	NHTyPYozPCCq	M2nyRWROW09?	NWnw[nM6cW6lcnXhd4V{KHSqZTDXRU1qdmS3Y3XkJIFxd3C2b4Ppdy=>	MnjFNlQxOTlyOUC=
HAPI	NH\OUohHfW6ldHnvckBCe3OjeR?=	NXHtfIhPOTBxMkCvOFDDqM7:TR?=	M37MZ\|EhcA>?		MVPpcohq[mm2czDUR2RFNWmwZIXj[YQheDN6L1rOT{BOSVCNIIDoc5NxcG:{eXzheIlwdg>?	NF\tXZEzOzl4OUGyNC=>
HAPI	MV7GeY5kfGmxbjDBd5NigQ>?	NF;5Z3kzOMLizszNxsA>	MlPvNUBp	M{XQTWROW09?	MXnheJRmdnWjdHXzJHRETERvaX7keYNm\CCjY4TpeoF1cW:wIH;mJIlPV1NiYX7kJJBzd2S3Y4Tpc44>	M3HoV\|I{QTZ7MUKw
HepG2	Mn\HSpVv[3Srb36gRZN{[Xl?	NIK0[lg{PTBibl2=	M4G4bFI1KGh?		M4PKb4lvcGmkaYTzJJRp\SCmZXf1[Yxqdi2rbnT1Z4VlKGGldHn2ZZRqd25ib3[gdFM5VUGSSx?=	NEPIXWYzOzl\|M{G5PC=>
AGS	M4L0U2Z2dmO2aX;uJGF{e2G7	NG\5WlkyOMLizszN	Mnn1N\|AhdWmw		MoPVbY5pcWKrdIOgZ4F{eGG\|ZT2zJIFkfGm4YYTpc44h[W6mIHnubIljcXSrb36gc4YhTVKN	NUPBbVhbOjN6NUC5PVQ>
HepG2	NX;JVHR6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUCwMVUxKM7:TR?=	MmP0OFghcA>?		MlThbY5pcWKrdIOgeIhmKHC{b3zp[oVz[XSrb36gbY4h[SCmb4PlJIRmeGWwZHXueEBu[W6wZYK=	NVXBS4IxOjN6MEe1NFg>
BEL7404	M{S1[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVOwMVUxKM7:TR?=	NULzOlNrPDhiaB?=		MUfpcohq[mm2czD0bIUheHKxbHnm[ZJifGmxbjDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?=	NX3ldJRYOjN6MEe1NFg>
HL7702	NHHJXItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlnUNE02OCEQvF2=	MUC0PEBp		NUTTZYdicW6qaXLpeJMhfGinIIDyc4xq\mW{YYTpc44hcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI>	M1PFXFI{QDB5NUC4
HepG2	MYDGeY5kfGmxbjDBd5NigQ>?	NF;tR\|MxNTVyIN88US=>	MkLTNlQhcA>?		MoHXbY5pcWKrdIOgeIhmKHCqb4PwbI9zgWyjdHnvckBw\iCyM{ig[I94dnO2cnXhcUBxem:2ZXnud{BOSVCNQWDLNkwhSVSIMjygUXNMOSCjbnSgTHNROjdiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ?	NUfJOmNNOjN6MEe1NFg>
BEAS-2B	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIq4TncyOCEQvF2=	NHfUb3I{OCCvaX6=		NImwcGhz\X[ncoPld{B1cGViZHXjdoVie2Vib3[gZ4VtdCC4aXHibYxqfHliaX7keYNm\CCkeTDIR2k>	NV\FToNROjN5OESwN\|Q>
BEAS-2B	Mn3IR5l1d3SxeHn0fUBCe3OjeR?=	MUKxNEDPxE1?	MlXDN\|AhdWmw		MoTrbY5pcWKrdHXkJJRp\SCrbnPy[YF{\SCrbjDMSGgh[W6mIFnMMVgh\XiycnXzd4lwdg>?	M37lUlI{Pzh2MEO0
BEAS-2B	NHvQ[oJHfW6ldHnvckBCe3OjeR?=	NEK3V20yOCEQvF2=	M3zyUFMxKG2rbh?=		NHHTcVFl\WO{ZXHz[ZMhfGinIHzleoVteyCxZjDjZZNx[XOnLUOsJGJi\CCjbnSg[oF{	MoG3NlM4QDRyM{S=
H9c2	NX:xZoViTnWwY4Tpc44hSXO\|YYm=	NYi5RXZjOC5yMT:wMlEwOSEQvF2=	MWGxJIg>		NGrLR3RifHSnboXheIV{KFSQRj5OtU1qdmS3Y3XkJG1OWC17IHX4dJJme3Orb36sJI1TVkFibHX2[Yx{NCCjbnSgdJJwdW:2ZYKgZYN1cX[rdIm=	M{Cxb\|I{Pzd2MkWy
H9c2	MXrGeY5kfGmxbjDBd5NigQ>?	Mm\XNUDPxE1?	MoT5NUBp		MWny[YR2[2W\|IGTOSk3PuSCmaYLlZ5RtgSC\|dHnteYxifGWmIICzPEBOSVCNIIDoc5NxcG:{eXzheIlwdg>?	NG\ocZEzOzd5NEK1Ni=>
U937	NYnVVGhUTnWwY4Tpc44hSXO\|YYm=	MWexNOKh\|ryPwrC=	NHPzUIsyKGh?		MXnhZpJw\2G2ZYOgeIhmKGOjZn\lbY5mKGWoZnXjeEBwdiCPS2CtNUBidmRiUGCyRYPPuSCvUl7BJJRz[W6\|Y4LpdJRqd26jbDDs[ZZmdHN?	NFvh[VUzOzdyN{O4Oy=>
U937	MlfnSpVv[3Srb36gRZN{[Xl?	MojTNVDDqM7:TdMg	M3nYbFEhcA>?		M{L5SoFjem:pYYTld{Bk[W[oZXnu[U1qdmS3Y3XkJG1MWC1zIHTve44uemWpdXzheIlwdiCjbnSgVHAzSWQQsTD1dE1z\We3bHH0bY9v	MViyN\|cxPzN6Nx?=
U937	NF;4WWlHfW6ldHnvckBCe3OjeR?=	MoTNNVDDqM7:TdMg	NVPtPWVwOSCq		NH;RUGV{fXCycnXzd4V{KGNvSoXuJIFv\CCFUlXCJJBpd3OyaH;yfYxifGmxbjDpckBk[W[oZXnu[U11emWjdHXkJINmdGy\|wrC=	MWKyN\|cxPzN6Nx?=
A549	NXHHOll[TnWwY4Tpc44hSXO\|YYm=	Ml\ENE4{NzNxM{Cg{txO	MnHaNUBp		MX7zbYdvcW[rY3HueIx6KGG2dHXueYF1\XNiQWTQ{tNUNW2nZHnheIVlKEORWD2yJJBzd3SnaX6gZY5lKG2UTlGg[ZhxemW\|c3nvckBidmRicILvcY91\XJiYXP0bZZqfHoEoB?=	MmX6NlM3QDB4N{S=
A549	M4TSSWZ2dmO2aX;uJGF{e2G7	NXz5NHBLOTEEoN88UeKh	MVuwMVMxKG2rbh?=		NWHid29VcW6qaXLpeJMhSVSSzsPTJIlv\HWlZXSgdFQzN3B2NDDNRXBMKGGwZDDwN\|ghVUGSSzDwbI9{eGixconsZZRqd25?	M3X5NFI{PjhyNke0
A549	NHf4eFJHfW6ldHnvckBCe3OjeR?=	M2nFflExyqEQvF5CpC=>	NUXiT5l5OSCq		M2nsS4lvcGmkaYTzJGFVWM7\|UzDpcoR2[2WmIF7GMe67SiCyNkWgd5VjfW6rdDDwbI9{eGixconsZZRqd25iYX7kJG5HNc78QjDwdo9ud3SncjDhZ5Rqfmm2eR?=	MmH0NlM3QDB4N{S=
A549	NYKyPJA3TnWwY4Tpc44hSXO\|YYm=	M2rlTlExyqEQvF5CpC=>	M3TrN\|EhcA>?		NGX5WGNz\WS3Y3XzJGFVWM7\|Uz3zeIlufWyjdHXkJINRVEF{IIDoc5NxcG:{eXzheIlwdsLi	NED2cXAzOzZ6ME[3OC=>
A549	NXfjSXJOTnWwY4Tpc44hSXO\|YYm=	M13PNFExyqEQvF5CpC=>	NGr6PZkyKGh?		MmTodoVlfWOnczDBWHDPu1NvZX7oZY5k\WRiZX76fY1ifGmlIHHjeIl3cXS7IH;mJINRVEF{wrC=	MmHhNlM3QDB4N{S=
PC12	MkTTSpVv[3Srb36gRZN{[Xl?	NWf4NY5bOTBxMkCvOFAh\|ryP	NVHwOpk6OcLiaB?=		Ml7kbY5pcWKrdIOgTm5MKGGwZDDwN\|g>	NEnmWokzOzV6NEO1Oy=>
HK-2	MkDURZBweHSxc3nzJGF{e2G7	MYiyNOKh\|ryP	MmTiNlQhcA>?		NIC4bJdqdmirYnn0d{BGWktiYX7kJJA{QE2DUFu=	Mn3XNlM2PDNzNUG=
H9c2	NELNOmlHfW6ldHnvckBCe3OjeR?=	NGfOS\|IyyqEQvF2=	NV7xXJVbOSCq		MVHy[YR2[2W\|IGTOSk3PuS2rbnT1Z4VlKE2PUD25JI1TVkFibHX2[Yx{KGGwZDDwdo9ud3SncjDhZ5Rqfmm2eR?=	MUSyN\|M2OzZ7OR?=
H9c2	M1v1UmZ2dmO2aX;uJGF{e2G7	M3LEcVHDqM7:TR?=	NV\o[Xp6OSCq		M3WyOJJm\HWlZYOgWG5HNc7zLXXubIFv[2WmIFHQMVEheHKxbX;0[ZIh[WO2aY\peJk>	NHH0Z24zOzN3M{[5PS=>
H1650	MUXGeY5kfGmxbjDBd5NigQ>?	NH7uT2QyOMLizszNxsA>	NFTPPIEyKGh?	NETQe3VFVVOR	NV64S3A2\GWlcnXhd4V{KGKxdHigdJJwfGWrbjDhcoQhdVKQQTDs[ZZmdHNib3[gSXJESzFiaX6gdIFkdGm2YYjlcE1mgHCxc3XkxsBk\Wyucx?=	MXGyN\|IzQDZ7Nh?=
H1703	M4XPVWZ2dmO2aX;uJGF{e2G7	MmTwNVDDqM7:TdMg	M2XlN\|EhcA>?	MmnlSG1UVw>?	MlzG[IVkemWjc3XzJIJwfGhicILveIVqdiCjbnSgcXJPSSCuZY\lcJMhd2ZiRWLDR\|EhcW5icHHjcIl1[XinbD3lfJBwe2WmwrDj[Yxtew>?	NELCSm0zOzJ{OE[5Oi=>
H1650	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnX3NVDDqM7:TdMg	NIDvNHMyKGh?	NVT2OXVKTE2VTx?=	MYflcohidmOnczDwZYNtcXSjeHXsMYlv\HWlZXSgZ5l1d3SxeHnjbZR6	NWTkbId{OjN{Mki2PVY>
H1703	NUnkNVdKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXXpbopwOTEEoN88UeKh	NV3aemI1OSCq	M4TWdmROW09?	M3rSOIVvcGGwY3XzJJBi[2yrdHH4[YwucW6mdXPl[EBkgXSxdH;4bYNqfHl?	MlnhNlMzOjh4OU[=

... Click to View More Cell Line Experimental Data

In vivo

Inhibiting p38 by administration of SB 202190 inhibits PV IgG-induced blister formation in the passive transfer mouse model. ^[5] In the endotoxin model of sepsis, SB 202190 treatment produces a statistically significant survival benefit compared with control. ^[8]

Protocol

Kinase Assay: ^[1]	+ Expand In vitro kinase assays: The p38α and p38β are assayed in 25 mM Tris-HCl, pH 7.5, containing 0.1 mM EGTA, with myelin basic protein (0.33 mg/mL) as substrate. Assays are performed either manually for 10 minutes at 30 °C in 50 μL incubations using [γ-³³P]ATP, or with a Biomek 2000 Laboratory Automation Workstation in a 96-well format for 40 minutes at ambient temperature in 25 μL incubations using [γ-³³P]ATP. The concentrations of ATP and magnesium acetate are 0.1 mM and 10 mM respectively. All assays are initiated with MgATP. Manual assays are terminated by spotting aliquots of incubation on to phosphocellulose paper, followed by immersion in 50 mM phosphoric acid. Robotic assays are terminated by the addition of 5 μL of 0.5 M phosphoric acid before spotting aliquots on to P30 filter mats. All papers are then washed four times in 50 mM phosphoric acid to remove ATP, once in acetone (manual incubations) or methanol (robotic incubations), and then dried and counted for radioactivity.
Cell Research: ^[2]	+ Expand Cell lines: Jurkat, and HeLa Concentrations: Dissolved in DMSO, final concentrations ~50 μM Incubation Time: 24 hours Method: Cells are serum-starved and then treated with different concentration of SB 202190 for 24 hours. Cell viability is assayed by either trypan blue exclusion or propidium iodide exclusion followed by flow cytometry analysis. The apoptotic nuclei are visualized by H33258 staining. (Only for Reference)
Animal Research: ^[5]	+ Expand Animal Models: C57BL/6J mice injected i.d. with a sterile solution of either control IgG or PV IgG Formulation: Dissolved in DMSO, and diluted in saline Dosages: 12.5 μg Administration: Administered via i.d. (Only for Reference)

References

+ Expand

Solubility (25°C)

In vitro	DMSO	66 mg/mL (199.19 mM)
	Ethanol	12 mg/mL (36.21 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 1% DMSO+30% polyethylene glycol+1% Tween 80 For best results, use promptly after mixing.	30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download SB202190 (FHPI) SDF

Molecular Weight	331.34
Formula	C₂₀H₁₄N₃OF
CAS No.	152121-30-7
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

p38 MAPK Signaling Pathway Map

p38 MAPK Inhibitors with Unique Features

Selective p38 MAPK Inhibitor

BIRB 796 (Doramapimod) : p38α-selective, Kd=0.1 nM.
Most Potent p38 MAPK Inhibitor

Skepinone-L ^New : p38α-MAPK, IC50=5 nM.
p38 MAPK Inhibitor in Clinical Trial

VX-702 : Phase II for Rheumatoid Arthritis.
Newest p38 MAPK Inhibitor

Skepinone-L ^New : Selective p38α-MAPK inhibitor with IC50 of 5 nM.

Related p38 MAPK Products4

Pexmetinib (ARRY-614) ^New

Pexmetinib (ARRY-614) is a potent, orally bioavailable, dual p38 MAPK/Tie-2 inhibitor with IC50 of 4 nM/18 nM in a HEK-293 cell line. Phase 1.
SB239063 ^New

SB239063 is a potent and selective p38 MAPKα/β inhibitor with IC50 of 44 nM, showing no activity against the γ- and δ-kinase isoforms.
Ravoxertinib (GDC-0994) ^New

GDC-0994 is a potent, orally available and highly selective ERK1/2 inhibitor with IC50 of 1.1 nM and 0.3 nM, respectively. Phase 1.
SB203580

SB203580 is a p38 MAPK inhibitor with IC50 of 0.3-0.5 μM in THP-1 cells, 10-fold less sensitive to SAPK3(106T) and SAPK4(106T) and blocks PKB phosphorylation with IC50 of 3-5 μM.

Features:First reported p38 inhibitor.
Doramapimod (BIRB 796)

Doramapimod (BIRB 796) is a pan-p38 MAPK inhibitor with IC50 of 38 nM, 65 nM, 200 nM and 520 nM for p38α/β/γ/δ in cell-free assays, and binds p38α with K_d of 0.1 nM in THP-1 cells, 330-fold greater selectivity versus JNK2, weak inhibition for c-RAF, Fyn and Lck, insignificant inhibition of ERK-1, SYK, IKK2.

Features:The first p38 MAPK inhibitor to be tested in a phase III clinical trial.
Ralimetinib (LY2228820)

Ralimetinib (LY2228820) is a novel and potent inhibitor of p38 MAPK with IC50 of 7 nM in a cell-free assay, does not alter p38 MAPK activation. Phase 1/2.
Losmapimod (GW856553X)

Losmapimod (GW856553X) is a selective, potent, and orally active p38 MAPK inhibitor with pK_i of 8.1 and 7.6 for p38α and p38β, respectively. Phase 3.
PH-797804

PH-797804 is a novel pyridinone inhibitor of p38α with IC50 of 26 nM in a cell-free assay; 4-fold more selective versus p38β and does not inhibit JNK2. Phase 2.
VX-702

VX-702 is a highly selective inhibitor of p38α MAPK, 14-fold higher potency against the p38α versus p38β. Phase 2.

Features:Highly selective, orally active inhibitor of p38 MAPK.
TAK-715

TAK-715 is a p38 MAPK inhibitor for p38α with IC50 of 7.1 nM, 28-fold more selective for p38α over p38β, no inhibition to p38γ/δ, JNK1, ERK1, IKKβ, MEKK1 or TAK1. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

SB202190 (FHPI)

Cited by 17 Publications

3 Customer Reviews

Purity & Quality Control

Choose Selective p38 MAPK Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download SB202190 (FHPI) SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Tech Support

p38 MAPK Signaling Pathway Map

p38 MAPK Inhibitors with Unique Features

Related p38 MAPK Products4

Choose Your Country or Region

By Signaling Pathways

By product type

SB202190 (FHPI)

Cited by 17 Publications

3 Customer Reviews

Purity & Quality Control

Choose Selective p38 MAPK Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download SB202190 (FHPI) SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Tech Support

p38 MAPK Signaling Pathway Map

p38 MAPK Inhibitors with Unique Features

Related p38 MAPK Products4

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)